It was reported by Singh et al. [19] that subclonal p53 immunostaining in endometrioid EC could be attributable to MMRd, and the subclonal nature of its expression likely reflects the acquisition of TP53 mutations as a later event during tumor progression. The gene discussed is TP53; the disease is neoplasm.